Natco Pharma Ltd.

Natco Pharma soars on getting USFDA's tentative approval for Olaparib tablets

NATCO will be manufacturing Olaparib tablets and its partner Alembic, would be distributing the product in the U.S

Natco Pharma gets USFDA's tentative approval for Olaparib tablets

NATCO will be manufacturing Olaparib tablets and its partner Alembic, would be distributing the product in the U.S

Natco Pharma informs about press release

Natco Pharma completes acquisition of additional 13.25% stake in Adcock Ingram

With the completion of this transaction, Natco’s shareholding in Adcock Ingram has increased from 35.75% to 49%

NATCO Pharma informs about disclosure

Natco Pharma gets nod to raise stake in Adcock Ingram to 49%

The acquisition is valued at Rs 1,069 crore at the prevailing exchange rate

Natco Pharma gets nod to invest up to Rs 1,400 crore in NPSAPL

The investment is expected to be completed before the end of July of 2026

Natco Pharma informs about press release

Natco Pharma, Lupin receive USFDA’s approval for Eribulin Mesylate Injection

Eribulin Mesylate Injection, 1 mg/2 mL Single-Dose Vials is the bioequivalent to the RLD Halaven Injection of Eisai, Inc

Natco Pharma reports 34% fall in Q4 consolidated net profit

Consolidated total income of the company decreased by 36.54% at Rs 816.90 crore for Q4FY26

Natco Pharma reports Profit after tax of Rs 2096.00 Mln, in the March 2026 quarter